Status:
TERMINATED
Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
Lead Sponsor:
Keio University
Conditions:
Lymphoma, Non-Hodgkin
Eligibility:
All Genders
18-69 years
Phase:
PHASE2
Brief Summary
Aggressive non-Hodgkin's lymphoma is difficult to handle once it relapses or becomes refractory to chemotherapy. Various second or third line chemotherapies, which are called salvage chemotherapy, wer...
Eligibility Criteria
Inclusion
- Clinical diagnosis of aggressive non-Hodgkin's lymphoma
- Refractory to the first line chemotherapy or relapsed
- Expression of CD20 on lymphoma cells
- Measurable lesions on imaging studies
Exclusion
- Blood cell counts not reaching to 3,000/microliter for white blood cells, 7 g/dl for hemoglobin, and 50,000/microliter for platelets without transfusion at the time of registration
- Circulating lymphoma cells equal to or more than 25,000/microliter
- Hepatic dysfunction
- Renal insufficiency
- Cardiac dysfunction or arrhythmia
- Sever infection (bacterial, viral)
- CNS involvement
- Other malignancies
- Pregnancy or breast feeding
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00367497
Start Date
August 1 2005
End Date
November 1 2007
Last Update
November 20 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Keio University School of Medicine
Tokyo, Japan, 160-8582